Sutro Biopharma Presents Nonclinical Data on STRO-002 Antibody-Drug Conjugate at 2022 AACR Annual Meeting
- Details
-
Category: Antibodies
-
Posted on Sunday, April 10, 2022 9:07 AM
-
Hits: 80
SOUTH SAN FRANCISCO, California, United States I April 8, 2022 I Sutro Biopharma, Inc. (“Sutro” or the “Company”) (NASDAQ: STR), a clinical-stage drug discovery, development and manufacturing company focused on applying precise protein engineering and rational design to create next-generation cancer therapies, announced today that new nonclinical data for its folate receptor alpha (FolRα)-targeting antibody-drug conjugate (ADC) STRO-002, during an e-poster session, at the 2022 American Association for Cancer Research Annual Meeting (AACR), to be held virtually and in New Orleans from April 8-13, 2022.
STRO-002 is an ADC designed to target FolRα, which is currently in phase 1 clinical trials for the treatment of ovarian and endometrial cancers. In the e-poster session presented at the AACR, studies in vitro demonstrate the ability of STRO-002 to induce immunogenic cell death characteristics. Studies live show that pre-administration of STRO-002 to FolRα-expressing tumor cells confers anti-tumor immunity, as demonstrated by both rejection of the primary tumor and significant protection after further tumor challenge. Further away, live the induction of immunogenic cell death extended to a complementary anti-tumor mechanism in association with a checkpoint inhibitor (avelumab) in rechallenged animals. Additionally, when STRO-002 was administered in combination with an anti-VEGF antibody (bevacizumab), tumor growth was significantly inhibited.
Non-clinical studies using xenograft models derived from endometrial and non-small cell lung cancer (NSCLC) patients with varying levels of FolRα expression have demonstrated robust STRO-002 activity, the degree of efficacy being correlated to the levels of FolRα. Similar activity was also observed in cells with moderate to low levels of FolRα expression. In the NSCLC model, a dose of STRO-002 of 10 mg/ml produced significant and long-term responses.
“These non-clinical data provide insight into the immunogenic cell death properties of STRO-002 and reveal its potential to elicit host immune system engagement and potentiate efficacy in a targeted and dependent manner,” said Trevor. Hallam, Ph.D., Research Chair and Scientific Director. Officer at Sutro. “The potent cytotoxic and immunostimulatory properties of STRO-002 through immunogenic cell death may also enhance activity in indications thought to have lower levels of FolRα, such as in non-small cell lung cancer and endometrial cancers.
The data is presented as an electronic poster at the AACR annual meeting, with the following details:
| Abstract: | #5591 |
| Session: | OPO.IMO2.01 – Preclinical immunotherapy |
| Title: | Anti-FolRα ADC STRO-002 induces immunogenic cell death (ICD) to enhance anti-tumor activity |
| Presenter: | Kristin Bedard, Ph.D., Vice President of Discovery at Sutro Biopharma |
The poster can be accessed through the Clinical/Scientific Presentation and Publication Highlights page in the News section of the company’s website at www.sutrobio.com.
About Sutro Biopharma
Sutro Biopharma, Inc., located in South San Francisco, is a clinical-stage drug discovery, development and manufacturing company. Through precise protein engineering and rational design, Sutro is advancing next-generation oncology therapies.
Sutro’s proprietary and integrated XpressCF® cell-free protein synthesis platform and XpressCF+™ site-specific conjugation platform led to the discovery of STRO-001 and STRO-002, the first two ADCs developed in-house by Sutro. Sutro. STRO-001 is a CD74-targeting ADC currently being studied in a Phase 1 clinical trial for patients with advanced B-cell malignancies and has received orphan drug designation from the FDA for multiple myeloma. STRO-002, an ADC targeting folate receptor alpha (FolRα), is currently being studied in a Phase 1 clinical trial for patients with ovarian and endometrial cancers and has received Fast designation FDA track for ovarian cancer. A third product candidate, CC-99712, an ADC targeting BCMAs, which is part of Sutro’s collaboration with Bristol Myers Squibb, formerly Celgene Corporation, is enrolling patients for its Phase 1 clinical trial in patients with multiple myeloma and has received orphan drug designation from the FDA. A fourth product candidate, M1231, a MUC1-EGFR bispecific ADC, which is part of Sutro’s collaboration with Merck KGaA, Darmstadt, Germany, known as EMD Serono in the United States and Canada (EMD Serono) , is recruiting patients for its Phase 1 clinical trial of patients with metastatic solid tumors, non-small cell lung cancer (NSCLC), and esophageal squamous cell carcinoma. These four product candidates are derived from Sutro’s XpressCF® and XpressCF+™ technology platforms. Bristol Myers Squibb and EMD Serono hold worldwide development and commercialization rights to CC-99712 and M1231, respectively, for which Sutro is entitled to milestone or contingent payments and tiered royalties.
Sutro is dedicated to transforming the lives of cancer patients by creating medicines with improved therapeutic profiles for areas of unmet need. To date, Sutro’s platform has led to ADCs, bispecific antibodies, cytokine-based immuno-oncology therapies and vaccines directed to previous targets in clinical indications where the current standard of care is suboptimal.
Sutro’s platform enables it to accelerate the discovery and development of potential first-in-class, best-in-class molecules through rapid and systematic assessment of protein structure-activity relationships to create optimized homogeneous product candidates. . In addition to developing its own oncology pipeline, Sutro collaborates with selected pharmaceutical and biotechnology companies to discover and develop novel, next-generation therapies.
Follow Sutro on Twitter, @Sutrobio and on www.sutrobio.com to learn more about our passion for changing the future of oncology.
THE SOURCE: Sutro Biopharma
